Press Release

MALVERN, Pa., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), today announced that it has appointed Brett Fair, an experienced executive within the field of dermatology, as Senior Vice President of Commercial Operations.

Mr. Fair brings more than 18 years of pharmaceutical commercialization and business development experience to Aclaris.  He has substantial experience with global pharmaceutical companies and has successfully launched products, grown product franchises, and transacted deals to build portfolios in the dermatology specialty area. 

"Brett’s industry insight, strategic perspective and operational experience will be extremely valuable to the Aclaris team as we continue to progress our lead program into Phase 3 clinical trials and further expand our development pipeline," said Dr. Neal Walker, President & CEO of Aclaris.  “Brett is an excellent addition to the team as we continue to build Aclaris into a fully integrated specialty dermatology company.”

Mr. Fair joins Aclaris from Aqua Pharmaceuticals where he served as the Vice President of Business Development. Prior to Aqua Pharmaceuticals, Mr. Fair held global commercial and business development roles at GlaxoSmithKline.  Mr. Fair started his career at Allergan where he held positions of increasing responsibility in sales and marketing.

About Aclaris

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology.  Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania and more information can be found by visiting the company’s website at www.aclaristx.com.

Contact:
Aclaris Contact
Dr. Neal Walker
President & CEO
484-324-7933
investors@aclaristx.com

Investor Contact
Patricia L. Bank
Westwicke Partners
Managing Director
415-513-1284
patti.bank@westwicke.com

Media Contact
Mike Beyer
Sam Brown, Inc.
312-961-2502
mikebeyer@sambrown.com 

Aclaris Therapeutics, Inc.